|
LRRC8B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.59739999958408E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.44169999999988E-05 |
| Normal-vs-Stage2 |
1.057060E-03 |
| Normal-vs-Stage3 |
9.08820000034005E-07 |
| Normal-vs-Stage4 |
4.48610000036709E-07 |
| Stage1-vs-Stage2 |
6.086600E-01 |
| Stage1-vs-Stage3 |
9.988300E-02 |
| Stage1-vs-Stage4 |
2.779900E-02 |
| Stage2-vs-Stage3 |
5.439200E-01 |
| Stage2-vs-Stage4 |
2.144800E-01 |
| Stage3-vs-Stage4 |
3.778000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.62950000007712E-07 |
| Normal-vs-AfricanAmerican |
2.097800E-02 |
| Normal-vs-Asian |
1.159380E-04 |
| Caucasian-vs-AfricanAmerican |
5.190200E-01 |
| Caucasian-vs-Asian |
6.167400E-01 |
| AfricanAmerican-vs-Asian |
3.837800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.84110000003945E-06 |
| Normal-vs-Female |
1.57040000003938E-06 |
| Male-vs-Female |
5.338200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.87609999999473E-05 |
| Normal-vs-Age(41-60Yrs) |
2.81040000160715E-08 |
| Normal-vs-Age(61-80Yrs) |
8.21640000000512E-05 |
| Normal-vs-Age(81-100Yrs) |
4.774800E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.228100E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.134800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.849600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.788000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.714200E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.149000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.420500E-02 |
| Classical-VS-Follicular |
5.027000E-01 |
| Classical-VS-Other |
2.299600E-01 |
| Classical-VS-Normal |
2.0046999999912E-05 |
| Tall-VS-Follicular |
1.787400E-01 |
| Tall-VS-Other |
7.646800E-01 |
| Tall-VS-Normal |
2.46130000003397E-06 |
| Follicular-VS-Other |
4.284400E-01 |
| Follicular-VS-Normal |
2.777800E-04 |
| Other-VS-Normal |
1.042170E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.95319999998878E-06 |
| Normal-vs-N1 |
4.3648999999979E-05 |
| N0-vs-N1 |
6.187600E-01 |
|
|
